BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 15757539)

  • 21. Apoptotic markers p53, Bcl-2 and Bax in primary lung cancer.
    Porebska I; Wyrodek E; Kosacka M; Adamiak J; Jankowska R; Harłozińska-Szmyrka A
    In Vivo; 2006; 20(5):599-604. PubMed ID: 17091766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma.
    Isa T; Tomita S; Nakachi A; Miyazato H; Shimoji H; Kusano T; Muto Y; Furukawa M
    Hepatogastroenterology; 2002; 49(45):604-8. PubMed ID: 12063950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Diagnostic value of p53 protein examination in lung cancer through preoperative fibro-optic bronchoscope brushing and biospy].
    Yu Q; Xiao Z; Liu G
    Zhonghua Zhong Liu Za Zhi; 1998 Nov; 20(6):445-7. PubMed ID: 10920941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Profiling of transcripts and proteins modulated by K-ras oncogene in the lung tissues of K-ras transgenic mice by omics approaches.
    Lee S; Kang J; Cho M; Seo E; Choi H; Kim E; Kim J; Kim H; Kang GY; Kim KP; Park YH; Yu DY; Yum YN; Park SN; Yoon DY
    Int J Oncol; 2009 Jan; 34(1):161-72. PubMed ID: 19082487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. X-radiation induces non-small-cell lung cancer apoptosis by upregulation of Axin expression.
    Han Y; Wang Y; Xu HT; Yang LH; Wei Q; Liu Y; Zhang Y; Zhao Y; Dai SD; Miao Y; Yu JH; Zhang JY; Li G; Yuan XM; Wang EH
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):518-26. PubMed ID: 19735876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung.
    Westra WH; Baas IO; Hruban RH; Askin FB; Wilson K; Offerhaus GJ; Slebos RJ
    Cancer Res; 1996 May; 56(9):2224-8. PubMed ID: 8616876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
    Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A mouse model for tumor progression of lung cancer in ras and p53 transgenic mice.
    Wang Y; Zhang Z; Lubet RA; You M
    Oncogene; 2006 Feb; 25(8):1277-80. PubMed ID: 16247444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53, erbB-2 and K-ras gene alterations are rare in spontaneous and plutonium-239-induced canine lung neoplasia.
    Tierney LA; Hahn FF; Lechner JF
    Radiat Res; 1996 Feb; 145(2):181-7. PubMed ID: 8606928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers.
    Akkiprik M; Ataizi-Celikel C; Düşünceli F; Sönmez O; Gulluoglu BM; Sav A; Ozer A
    J Gastrointestin Liver Dis; 2007 Mar; 16(1):11-7. PubMed ID: 17410283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 and K-ras in radon-associated lung adenocarcinoma.
    McDonald JW; Taylor JA; Watson MA; Saccomanno G; Devereux TR
    Cancer Epidemiol Biomarkers Prev; 1995; 4(7):791-3. PubMed ID: 8672998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes.
    Fisher GH; Wellen SL; Klimstra D; Lenczowski JM; Tichelaar JW; Lizak MJ; Whitsett JA; Koretsky A; Varmus HE
    Genes Dev; 2001 Dec; 15(24):3249-62. PubMed ID: 11751631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sequence distribution of acetaldehyde-derived N2-ethyl-dG adducts along duplex DNA.
    Matter B; Guza R; Zhao J; Li ZZ; Jones R; Tretyakova N
    Chem Res Toxicol; 2007 Oct; 20(10):1379-87. PubMed ID: 17867647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Restoration of wild-type p53 activity enhances the sensitivity of pleural metastasis to cisplatin through an apoptotic mechanism.
    Riva CM
    Anticancer Res; 2000; 20(6B):4463-71. PubMed ID: 11205289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The differential effects of mutant p53 alleles on advanced murine lung cancer.
    Jackson EL; Olive KP; Tuveson DA; Bronson R; Crowley D; Brown M; Jacks T
    Cancer Res; 2005 Nov; 65(22):10280-8. PubMed ID: 16288016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer.
    Grote HJ; Schmiemann V; Geddert H; Bocking A; Kappes R; Gabbert HE; Sarbia M
    Cancer; 2006 Apr; 108(2):129-34. PubMed ID: 16444703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
    Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
    Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [DNA content analysis and detection of c-myc and p53 products using flow cytometry in resected lung cancer cases].
    Chiba W; Sawai S; Ikeda S; Morimoto K; Wazawa H; Hanawa T; Yamashita N; Matsui T; Hatakenaka R; Matsubara Y
    Gan To Kagaku Ryoho; 1994 May; 21 Suppl 1():108-16. PubMed ID: 8203922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The value of serum tumor marker in the diagnosis of lung cancer].
    Shi GL; Hu XL; Yue SD; Song CX
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):299-301. PubMed ID: 15996327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.